GLP-1r Agonist Crystal Forms for Stable Drug Manufacturing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing GLP-1 agonists like Compound A face challenges in developing solid forms suitable for large-scale manufacture, storage stability, and bioavailability due to issues such as water absorption and transformation into other forms.
Innovation Solution
The development of three new crystalline forms of Compound A free acid, namely Forms I, II, and III, which are physically and chemically stable, have high melting points, and are suitable for pharmaceutical formulations, ensuring ready isolation, purification, and absorption.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Compound A is synthesized as a free acid, then it exhibits GLP-1 agonist activity, but it absorbs water and transforms into other solid forms, reducing storage stability
Solution Approach 1:
The patent applies parameter changes by modifying the physical state parameters of Compound A through crystallization. By controlling crystallization conditions (solvent selection, temperature, pH), the patent transforms the unstable free acid into stable crystalline forms with defined lattice structures, thereby changing the physical parameters (solubility, hygroscopicity, melting point) to achieve storage stability while maintaining GLP-1 agonist activity.
Solution Approach 2:
The patent utilizes phase transitions by inducing crystallization of Compound A from solution or melt states into solid crystalline forms. This phase transition from amorphous/unstable solid to ordered crystalline solid fundamentally changes the material's properties, reducing water absorption and preventing transformation into other solid forms, thus resolving the storage stability issue.
2Ease of manufacture
If crystalline forms are developed for large-scale manufacture, then isolation and purification become easier, but the development process requires identification of suitable solid forms with specific properties
Solution Approach 1:
The patent applies preliminary action by pre-establishing multiple crystalline forms (Forms I, II, III) with characterized properties before large-scale manufacture. The patent describes systematic crystallization protocols and characterization methods that are developed in advance, allowing straightforward selection of the most suitable form for manufacturing without requiring complex real-time decision-making during production.
Solution Approach 2:
The patent segments the solid form development into distinct, well-defined crystalline forms (Form I, Form II, Form III), each with specific characteristics. This segmentation allows the manufacturing process to select and produce only the required form, simplifying isolation and purification by targeting specific crystal structures with distinct physical properties rather than dealing with a continuum of possible solid forms.
3Reliability
If the crystalline form has high melting point and stability, then storage is improved, but solubility and absorption may be reduced
Solution Approach 1:
The patent applies parameter changes by creating multiple crystalline forms with different physical parameters. Forms I, II, and III exhibit different melting points, solubilities, and hygroscopicity values. This allows selection of the optimal form based on the intended application - Forms with lower melting points and higher solubility for formulations requiring rapid dissolution, and forms with higher stability for long-term storage applications.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These crystalline forms provide enhanced stability and bioavailability, making them suitable for treating cardiometabolic diseases by maintaining therapeutic efficacy and reducing side effects.
Implementation Method 1
three new crystalline forms of Compound A free acid, which can be obtained under well-defined conditions to provide desired crystalline forms
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Crystalline forms of Compound (A) represented by the following structural formula, and their corresponding pharmaceutical compositions, are disclosed. The crystalline forms are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms are also disclosed. The present disclosure also provides methods of treating or preventing diseases or conditions such as type 2 diabetes mellitus, pre-diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cardiovascular disease in a subject.